ARS Pharmaceuticals
SPRY
89 hedge funds and large institutions have $348M invested in ARS Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 32 increasing their positions, 17 reducing their positions, and 10 closing their positions.
482% more call options, than puts
Call options by funds: $5.9M | Put options by funds: $1.01M
170% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 10
88% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 17
24% more funds holding
Funds holding: 72 → 89 (+17)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
18% less capital invested
Capital invested by funds: $425M → $348M (-$77.3M)
81.59% less ownership
Funds ownership: 138.19% → 56.59% (-82%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$7.71M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$5.8M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.77M |
| 4 |
RA
Royce & Associates
New York
|
+$2.33M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$5.08M |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$2.71M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.16M |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.56M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$1.43M |
SPRY Hedge Fund Activity: Q1 2023 in Review
89 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2023, worth a combined $348M — down 18% from $425M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SPRY positions and 10 closed out — a net gain of 17 holders — while 32 added to existing stakes and 17 trimmed.
The largest buyer was SR One Capital Management, adding an estimated $7.71M. The largest seller was Woodline Partners, cutting an estimated $5.08M.
- 89 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2023, up from 72 in Q4 2022.
- Funds reported $348M of ARS Pharmaceuticals stock for Q1 2023, down 18% quarter-over-quarter.
- 27 funds opened new ARS Pharmaceuticals positions in Q1 2023 and 10 closed out, a net change of +17 holders.
- The largest ARS Pharmaceuticals buyer in Q1 2023 was SR One Capital Management, an estimated $7.71M added.
- The largest ARS Pharmaceuticals seller in Q1 2023 was Woodline Partners, an estimated $5.08M sold.
Based on aggregated 13F filings for Q1 2023.